Lucid Diagnostics (LUCD) traded up 21.9 % during a 24 hours period ending at 10:12 AM Central Europe on Tuesday 27th. One Lucid Diagnostics stock can currently be bought for about USD 0.5 on popular exchanges. Current supply of Lucid Diagnostics stocks is 169.6 mn. Lucid Diagnostics has a current market capitalization of USD 78.5 mn and approximately USD 21.6 mn worth of Lucid Diagnostics was traded on exchanges in the last 24 hours. Since last month end, Lucid Diagnostics has traded -37.84 % down. Simple moving average of last 200 days is at USD 1.04. The highest price of past 52 weeks was recorded at USD 1.63 on 01/21/2026. 52 weeks low was at USD 0.3 on 10/22/2026.
Here is how related stocks have performed in the past 24 hours:
Netsol (NTWK) traded down -2.04 % and now trades at USD 7.7. Current market capitalisation for Netsol is USD 92 mn. Netsol has a current price to earnings ratio of 32.99.
Neuraxis (NRXS) traded down -2.03 % and now trades at USD 7.25. Neuraxis has a market capitalisation of USD 92.9 mn.
Coya Therapeutics (COYA) traded up 0.25 % and now trades at USD 3.95. Coya Therapeutics has a market capitalisation of USD 92.4 mn.
Polaryx Therapeutics (PLYX) traded down -1.62 % and now trades at USD 1.82. Polaryx Therapeutics has a market capitalisation of USD 92.2 mn.
Immucell (ICCC) traded down -0.1 % and now trades at USD 10.24. Immucell has a market capitalisation of USD 93.1 mn. Current price/earnings ratio for Immucell is 137.53.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company based in New York, United States. The company specializes in developing products to diagnose and treat conditions of the esophagus, particularly focusing on conditions resulting from chronic heartburn that may lead to esophageal cancer. You can find more information about the company and their offerings on their website, www.luciddx.com , and they are listed on the Nasdaq stock exchange.
